<DOC>
	<DOCNO>NCT01410916</DOCNO>
	<brief_summary>This protocol design collect safety efficacy data patient treat eculizumab STEC-HUS , context 2011 STEC-HUS epidemic Germany .</brief_summary>
	<brief_title>Safety Efficacy Study Eculizumab Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome ( STEC-HUS )</brief_title>
	<detailed_description />
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Shiga Toxins</mesh_term>
	<criteria>1 . Patient must willing able give write informed consent/Assent . 2 . Adults , adolescent , pediatric ( ≥2 month ≥5kg ) patient 3 . Patient diagnose Escherichia Coli HemolyticUremic Syndrome ( STECHUS ) 1 . Known complement regulatory mutation family history complement regulatory mutation 2 . Unresolved systemic meningococcal disease 3 . 3 . Hypersensitivity eculizumab , murine proteins one excipients</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>STEC-HUS</keyword>
	<keyword>Shiga-like toxin-producing Escherichia Coli Hemolytic-Uremic Syndrome</keyword>
	<keyword>uncontrolled complement activation</keyword>
</DOC>